TAGCyx Biotechnologies, Inc.

TAGCyx Biotechnologies, Inc. is a Japanese firm specializing in the development of innovative nucleic acid drugs utilizing proprietary technology for precision binding to target molecules, with applications in various medical conditions. Established in 2007 and headquartered in Tokyo, Japan, TAGCyx Biotechnologies focuses on high-performance nucleic acid therapies. The company has completed 4 investment deals, with its most recent funding in July 2021, raising JPY 210 million from investors including Healthcare Innovation and the University of Tokyo Innovation Platform.

CEO Chizuko Koseki leads the company in advancing its innovative drug discovery methods, aiming to enhance medical treatment options. TAGCyx Biotechnologies specializes in high-performance nucleic acid drugs, offering advanced aptamers and its proprietary Xenoligo® technology. These products target medical conditions such as interstitial cystitis, dry eye associated with Sjögren's syndrome, alopecia areata, thrombotic thrombocytopenic purpura, and gestational hypertension nephropathy, with a focus on expanding into international markets including North America and Europe. TAGCyx Biotechnologies generates revenue through B2B partnerships and collaborations with academic institutions and pharmaceutical companies.

Revenue streams include licensing agreements, research grants, and collaborative product development contracts, particularly centered around their flagship products like Xenoligo® and proprietary aptamers, with payments structured around project milestones and royalties from successful commercialization. Following its most recent funding of JPY 210 million in July 2021, TAGCyx Biotechnologies aims to build a robust pipeline and advance its drug discovery processes. The company plans to launch new product developments targeting unmet medical needs and to expand its market reach to North America and Europe, leveraging this funding to expedite its contributions to medical care.